To include your compound in the COVID-19 Resource Center, submit it here.

Cleveland BioLabs, U.S. Department of Defense other news

Cleveland BioLabs received an additional $1.5 million from the DoD to develop CBLB502 to treat acute radiation syndrome (ARS),

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE